The subtype‐specific molecular function of SPDEF in breast cancer and insights into prognostic significance

Breast cancer (BC) is a molecular diverse disease which becomes the most common malignancy among women worldwide. There are four BC subtypes (Luminal A, Luminal B, HER2‐enriched and Basal‐like) robustly established following gene expression pattern‐based characterization, behave significant differen...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cellular and molecular medicine 2021-08, Vol.25 (15), p.7307-7320
Main Authors: Ye, Ting, Li, Jingyuan, Feng, Jia, Guo, Jinglan, Wan, Xue, Xie, Dan, Liu, Jinbo
Format: Article
Language:English
Subjects:
Bioinformatics
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Biomarkers, Tumor - standards
Breast cancer
Breast Neoplasms - classification
Breast Neoplasms - genetics
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
Datasets
ErbB-2 protein
Female
Gene expression
Humans
Malignancy
Medical prognosis
Medical research
Middle Aged
molecular function
Original
Prognosis
prognostic significance
Prostate
Protein expression
Proteins
Proto-Oncogene Proteins c-ets - genetics
Proto-Oncogene Proteins c-ets - metabolism
Proto-Oncogene Proteins c-ets - standards
Risk factors
Sensitivity and Specificity
Signal transduction
Software
SPDEF
subtype‐specific
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Breast cancer (BC) is a molecular diverse disease which becomes the most common malignancy among women worldwide. There are four BC subtypes (Luminal A, Luminal B, HER2‐enriched and Basal‐like) robustly established following gene expression pattern‐based characterization, behave significant differences in terms of their incidence, risk factors, prognosis and therapeutic sensitivity. Thus, there is an urgent need to provide mechanism research, treatment strategies and/or prognosis evaluation based on the patient stratification of BC subtypes. The prostate‐derived ETS factor SPDEF was first identified as an activator of prostate specific antigen, and then, the involvements in many aspects of BC have been proposed. However, the subtype‐specific molecular function of SPDEF in BC and insights into prognostic significance have not been clearly elucidated. This study demonstrated for the first time that SPDEF may play a diversity role in the expression levels, clinicopathologic importance, biological function and prognostic evaluation in BC via bioinformatics and experimental evidence, which mainly depends on different BC subtyping. In summary, our findings would help to better understand the possible mechanisms of various BC subtypes and to find possible candidate genes for prognostic and therapeutic usage.
ISSN:1582-1838
1582-4934
DOI:10.1111/jcmm.16760